Gister het die Amerikaanse FDA die goedkeuring aangekondig van Seattle Genetics se teenliggaam-geneesmiddel-konjugaat Adcetris (brentuximab vedotin) in kombinasie met chemoterapie vir pasiënte met voorheen behandelde stadium III of IV klassieke Hodgkin se limfoom (cHL). Hierdie goedkeuring verteenwoordig 'n verbetering in die aanvanklike behandelingsplan vir gevorderde Hodgkin limfoom wat meer as 40 jaar gelede in die kliniese praktyk ingestel is.
Lymphoma is a type of cancer that begins in the lymphatic system. The immune system helps the body fight infections and diseases. Lymphoma can develop almost anywhere in the body and can spread to nearby lymph nodes. It is divided into two types: Hodgkin limfoom and non-Hodgkin lymphoma. Most patients with Hodgkin limfoom belong to the classic type. In this type of lymph node, there are large abnormal lymphocytes (a type of white blood cell). Called Reed-Sternberg cells. Through early intervention, patients with Hodgkin’s lymphoma usually get long-term remission.
In 'n kliniese proef is die potensiaal van Adcetris om klassieke Hodgkin-limfoom te behandel, bekragtig - die navorsers het 1,334 6 behandelde pasiënte gewerf wat voorheen gemiddeld 28 kursusse van 23 dae siklusse ontvang het. Vervolgens is hulle in twee groepe verdeel, een groep het Adcetris en chemoterapie (AVD) ontvang, en die ander groep het slegs chemoterapie (ABVD) ontvang. Studies het getoon dat pasiënte wat 'n kombinasie-terapie ontvang, 'n XNUMX% laer risiko het om siektes te vorder, te sterf of dat hulle moet begin met nuwe behandeling in vergelyking met pasiënte wat slegs chemoterapie ontvang.
Adcetris combines antibodies and drugs, allowing antibodies to direct drugs to limfoom selle called CD30, approved for treatment of relapsed classic Hodgkin lymphoma, classic Hodgkin lymphoma with high risk of relapse or progression after stem cell transplantation, accepted Systemic anaplastic large cell lymphoma that other treatments are not effective, and primary cutaneous anaplastic large cell lymphoma that does not work with other treatments.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
